Last $11.71 USD
Change Today +0.49 / 4.37%
Volume 4.1M
ACHN On Other Exchanges
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

achillion pharmaceuticals (ACHN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/4/14 - $13.80
52 Week Low
10/31/13 - $2.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

achillion pharmaceuticals (ACHN) Related Businessweek News

No Related Businessweek News Found

achillion pharmaceuticals (ACHN) Details

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

61 Employees
Last Reported Date: 03/7/14
Founded in 1998

achillion pharmaceuticals (ACHN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $435.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $326.4K
Chief Compliance Officer and Executive Vice P...
Total Annual Compensation: $334.4K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $313.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $256.7K
Compensation as of Fiscal Year 2013.

achillion pharmaceuticals (ACHN) Key Developments

Achillion Pharmaceuticals, Inc. Enters into Master Security Agreement for $1,000,000 Capital Expenditure Line of Credit with Webster Bank, National Association

On October 3, 2014, Achillion Pharmaceuticals, Inc. entered into a master security agreement for a $1,000,000 capital expenditure line of credit with Webster Bank, National Association. Under the credit facility, Achillion may take equipment loan advances for the purchase of new laboratory equipment through October 3, 2015. Each advance will be payable over a three year term and bear interest at a fixed rate, determined at the time of each advance, equal to the three year Federal Home Loan Bank of Boston classic advance rate plus 4.75%. In connection with the Agreement, Achillion paid Webster a $10,000 origination fee and will reimburse Webster for all reasonable fees and expenses incurred in connection with the agreement. The purchased equipment will serve as collateral for the advances. The obligations of Achillion under the agreement may be accelerated upon the occurrence of an event of default, which includes customary events of default, including without limitation payment defaults, defaults in obligations, the inaccuracy of representations or warranties and bankruptcy and insolvency related defaults.

Achillion To Buy Gilead

Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN) is looking to buy Gilead Sciences, Inc. (NASDAQ:GILD). Shares of Achillion have appreciated 389% since June 2014 on acquisition talks.

Achillion Pharmaceuticals, Inc. Presents at FBR Inaugural Healthcare Conference, Sep-03-2014

Achillion Pharmaceuticals, Inc. Presents at FBR Inaugural Healthcare Conference, Sep-03-2014 . Venue: Four Seasons Boston, 200 Boylston Street, Boston, MA 02116, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $11.71 USD +0.49

ACHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACHN.
View Industry Companies

Industry Analysis


Industry Average

Valuation ACHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at